Recent Updates
Recently added Catalysts
LGND Positive Sentiment

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Tuesday, September 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sydnexis, Inc. has entered into a royalty agreement with Ligand Pharmaceuticals, allowing Ligand to acquire rights to net sales of Ryjunea® in Europe, the Middle East, and Africa. This agreement includes a substantial upfront payment of $23 million. The collaboration aims to bolster Ligand's offerings in treating pediatric progressive myopia.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sydnexis secures a significant upfront payment of $23 million.
  • The agreement enhances Ligand's portfolio in the pediatric myopia treatment space.
  • The partnership may lead to increased market presence in EMEA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
2.6%
average across 2 past catalysts
Lead asset
lasofoxifene
Phase 3 · Osteoporosis

Full Press Release Details

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the agreement, Ligand will pay $23 million upfront to acquire a 100% interest in certain payments an

Frequently Asked Questions

What is the focus of Sydnexis, Inc.?

Sydnexis, Inc. focuses on developing a low-dose atropine formulation for pediatric progressive myopia.

How much will Ligand pay for the royalty rights?

Ligand will pay $23 million upfront for the royalty rights associated with Ryjunea®.

In which regions does the agreement apply?

The agreement covers net sales of Ryjunea® in Europe, the Middle East, and Africa.

What is Ryjunea® used to treat?

Ryjunea® is used to treat pediatric progressive myopia.

ShareAdd on Google
Tags: LGND Viatris Investor Conferences Healthcare Sydnexis Ligand Ryjunea pediatric myopia royalty agreement
Last updated: Sep 22, 2026

Biotech snapshot

Cash runway
$1358M liquidity · $0M/mo burn
Low dilution risk
Lead asset
lasofoxifenePhase 3
Osteoporosis →

Catalyst track record

+67%
best trade around LGND's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for LGND.

See every catalyst's timing & PoA →